BRCA2 and breast cancer: Furthermore, using neoantigen data reported by Rooney et al. [33], the median number of predicted neoantigens in TCGA BRCA1- and BRCA2-deficient breast cancers were observed to be 2.3 and 2.5 fold higher, respectively, compared to BRCA-proficient breast cancers (P = 5.4 x 10−7 and 3.3 x 10−6, respectively; S4 Fig).